Loading…
Loading…
West Pharmaceutical Services, Inc. (NYSE:WST) reported better than expected second quarter 2026 earnings. The injectable solutions company reported adjusted earnings of $2.37 per share, beating the consensus of $2.08.
LLY's blockbuster GLP-1 portfolio takes center stage as investors watch Mounjaro, Zepbound and Foundayo for clues to Q2 growth and outlook.
The increasing rate of patients using GLP-1 medications is now boosting growth in Galderma's aesthetics portfolio, CEO Flemming Ørnskov told CNBC on Thursday. About 10% of U.S. adults now report taking GLP-1 drugs for weight loss, which may boost demand for treatments like fillers and anti-wrinkle injections.
Novo Nordisk has sued rival GLP-1 drugmaker Eli Lilly in federal court, alleging misleading advertising. Novo alleges that Lilly's ads compare a lower dosage of its weight loss drug Wegovy to the highest dose of its own weight loss drug Zepbound.
Novo Nordisk (NYSE:NVO) has filed a federal lawsuit against Eli Lilly, alleging that its rival's advertising campaigns for blockbuster GLP-1 obesity and diabetes drugs mislead consumers about the effectiveness of competing treatments. The complaint, filed on July 21, 2026, in the US District Court for the District of New Jersey, challenges nationwide advertisements for Lilly's Zepbound and Mounjaro that Novo claims rely on outdated clinical trial data and create an inaccurate comparison between the companies' medicines.
LLY's leadership in obesity drugs, expanding pipeline and stronger growth outlook set it apart as investors weigh it against NVO in 2026.
Ozempic drugmaker Novo Nordisk sued rival GLP-1 manufacturer Eli Lilly in federal court Tuesday, accusing the company of using “intentionally selected outdated studies” to curate allegedly misleading ad campaigns that exaggerate the efficacy of Lilly's products.
The drugmaker says Lilly isn't including the most up-to-date clinical information about its drugs
SEC filings for GLP aren't indexed yet — common for recently launched funds. Browse the issuer's filings on SEC EDGAR directly.